Clinical Pharmacology Adaptive Therapy Group
Professor Banerji's group aims to study re-wiring of signal transduction to understand and overcome mechanisms of drug resistance and, in addition, to understand exploit cancer evolution using pharmacological tools.
We are focused on the re-wiring of signal transduction using established cell lines to control mechanisms of drug resistance and comprehend the evolution of cancer.
Rewiring of signal transduction
This group is working on the set-up and validation of a highly sensitive antibody-based assay on the Nanostring platform which will allow quantification of 50 - 100 phosphoproteins/proteins. It plans to digest tumour tissue obtained during surgery or from biopsies and expose them to a matrix of 20 - 30 anticancer drugs before obtaining phosphoproteomic data.
It also aims to use organoids and patient-derived xenografts to take this forward. The proteomic data will be modelled with the Computational Biology and Chemogenomics Team led by Professor Bissan Al-Lazikani. The group also supports PhD students studying the re-wiring of signal transduction in colon cancer and the role of stroma in influencing signal transduction.
The group also currently works with Professor Andrea Sottoriva at the Centre for Evolution and Cancer at the ICR to look at barcoding of cancer cells and the study of evolutionary trajectories of clones under experimental conditions. It is also studying mechanisms of resistance, collateral drug sensitivity and resistance of these emergent clones.
The primary area of this group is focused on the re-wiring of signal transduction using established cell lines as well as fresh cancer cells derived and isolated from patients and then exposing them to novel anticancer drugs. Pre- and post-proteomic profiling provides insights into mechanisms of drug resistance and how to overcome this with combination therapies. The initial work was carried out using cancer cells isolated from ascites and pleural effusions; the group in now developing expertise in organoid and patient-derived xenograft tissue.
The group develops its own antibody-based proteomic platforms and collaborates with teams involved in mass spectroscopic methods, led by Jyoti Choudhary. The group generates significant amounts of data and collaborates with the ICR's Computational Biology and Chemogenomics Team led by Professor Bissan Al-Lazikani to develop and decipher the data.
The secondary focus of this lab is the study of the pharmacological effects on cancer evolution in experimental models and methods to quantify this and herd cancer cells to a vulnerable state.
Professor Banerji works with Professor Andrea Sottoriva in the Centre for Evolution and Cancer at the ICR and plans to translate these concepts in to the clinic.
Professor Udai Banerji
Group Leader:
Clinical Pharmacodynamics Biomarker Group, Clinical Pharmacology & Trials, Clinical Pharmacology Adaptive Therapy Group
Professor Udai Banerji champions multidisciplinary working at the interface between early phase clinical trials, drug discovery and translational research related to drug resistance. He is Deputy Director of the Drug Development Unit at The ICR and Royal Marsden, and as a key member of the Centre for Cancer Drug Discovery, also heads the Clinical Pharmacodynamics Biomarker Group and the Clinical Pharmacology-Adaptive Therapy Group.
Researchers in this group
.
Professor Udai Banerji's group have written 138 publications
Most recent new publication 1/2025
See all their publicationsVacancies at the ICR
Working at the ICR
Head of Biology and Director, Centre for Target Validation (Group Leader)
Under the leadership of Dr Olivia Rossanese, we are seeking to appoint a Team Leader to join The Centre for Cancer Drug Discovery (CCDD) as The Head of Biology and Director of the Centre for Target Validation. Key Requirements The successful candidate must have in-depth knowledge and recent experience in an area of cancer biology relevant to oncology drug discovery. Leadership experience of drug discovery within, or in collaboration with, the pharmaceutical or biotechnology industry as evidenced by publication and/or successful commercial projects. Along with completing the online application form, you will be asked to attach the following documents and failure to do so will mean your application cannot be considered on this occasion: · Full CV · Lists of major publications, achievements, research grants, distinctions. · A PDF of a maximum of five key publications, or other research outputs (e.g. patents) that best demonstrate previous productivity · You must also complete the personal statement section of the application form in the format of a covering letter including the names and contact details of three academic referees Department/Directorate Information: The Division of Cancer Therapeutic's mission is to develop personalised medicines by translating information from the cancer genome and cancer biology into drugs for patient benefit. We implement innovative drug discovery technologies, discover novel mechanism-based drugs, and develop these as rapidly as possible from the laboratory through to hypothesis-testing early clinical trials We encourage all applicants to access the job pack attached for more detailed information regarding this role. For an informal discussion regarding the role, please contact Dr Olivia Rossanese, Email [email protected]
Postdoctoral Training Fellow
Under the leadership of Claudio Alfieri, we are seeking to appoint a Postdoctoral Training Fellow to join the Molecular Mechanisms of Cell Cycle Regulation Group at the Chester Beatty Laboratories, Fulham Road in London. This project aims to investigate the molecular mechanisms of cell cycle regulation by macromolecular complexes involved in cell proliferation decisions, by combining genome engineering, proteomics and in situ structural biology. For general information on Post Doc's at The ICR can be found here. Key Requirements The successful candidate must have a PhD in cellular biochemistry and experience in Cryo-EM and CLEM is desirable. The ICR has a workforce agreement stating that Postdoctoral Training Fellows can only be employed for up to 7 years as PDTF at the ICR, providing total postdoctoral experience (including previous employment at this level elsewhere) does not exceed 10 years Department/Directorate Information: The candidate will work in the Molecular Mechanisms of Cell Cycle Regulation Group within the ICR Division of Structural Biology headed by Prof. Laurence Pearl and Prof. Sebastian Guettler. The division has state-of-the-art facilities for protein expression and biophysics/x-ray crystallography, in particular the Electron Microscopy Facility is equipped with a Glacios 200kV with Falcon 4i detector with Selectris energy filter and the ICR has access to Krios microscopes via eBIC and the LonCEM consortium. We encourage all applicants to access the job pack attached for more detailed information regarding this role. For an informal discussion regarding the role, please contact Claudio Alfieri via Email on [email protected]
Employee Story
Dr Fatemeh Ahmadi Moughari is a bioinformatician working in the Functional Genomics Team, led by Rachael Natrajan, and the Bioinformatics Team, led by Syed Haider. She joined the ICR from her home country of Iran where she completed her PhD in anti-cancer drug response at Shahid Beheshti University.
"I really enjoy the multidisciplinary atmosphere here and it’s the thing that stood out when I first joined the ICR."
Industrial partnership opportunities with this group
Opportunity: A potent, orally bioavailable clinical-stage inhibitor of MPS1 with potential as a treatment for a range of cancer types including triple negative breast cancer
Commissioner: Swen Hoelder
